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Abstract 
With dengue virus (DENV) becoming endemic in tropical and subtropical regions worldwide, 
there is a pressing global demand for effective strategies to control the mosquitoes that spread this 
disease. Recent advances in genetic engineering technologies have made it possible to create 
mosquitoes with reduced vector competence, limiting their ability to acquire and transmit 
pathogens. Here we describe the development of Aedes aegypti mosquitoes synthetically 
engineered to impede vector competence to DENV. These mosquitoes express a gene encoding an 
engineered single-chain variable fragment derived from a broadly neutralizing DENV human 
monoclonal antibody and have significantly reduced viral infection, dissemination, and 
transmission rates for all four major antigenically distinct DENV serotypes. Importantly, this is 
the first engineered approach that targets all DENV serotypes, which is crucial for effective disease 
suppression. These results provide a compelling route for developing effective genetic-based 
DENV control strategies, which could be extended to curtail other arboviruses. 
 
Significance Statement 
Here we describe the development of Ae. aegypti mosquitoes synthetically engineered to impede 
vector competence to multiple serotypes of DENV. Given the global significance of DENV, these 
mosquitoes may be used to curtail Dengue transmission by this potent vector. 
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Introduction 
Dengue fever is a devastating viral disease caused by several antigenically distinct dengue 
viral (DENV) serotypes that are all dangerous to humans but cannot be readily controlled using 
broad-spectrum techniques1,2. Transmitted by infected mosquitoes, DENV infection typically 
manifests as severe fever, headaches, and myalgia3 and can advance to the life-threatening dengue 
hemorrhagic fever and dengue shock syndrome4. Global incidences of DENV and its associated 
economic burden have increased dramatically in recent years5,6, with over 50% of the world’s 
population now at risk of infection7 and 390 million documented infections per year6 for an 
estimated $40 billion in economic losses annually8,9. Moreover, there are currently no specific 
treatments nor preventive prophylactic measures10 because the single commercially available 
vaccine11 is only partially effective12, and due to increased risk of severe dengue illness and 
hospitalization among certain groups, its use is prevented in many contexts13–15. Therefore, control 
of the disease-spreading mosquitoes is currently the best option for preventing DENV 
transmission13.  
Aedes aegypti16, the main vector of DENV and other epidemiologically significant viruses 
such as chikungunya (CHIKV), yellow fever (YFV), and Zika (ZIKV), is a domestic endophilic 
mosquito17 that has expanded its habitable range in recent decades18 and will likely continue to 
spread19. Current control measures including the removal of standing water and the use of chemical 
insecticides have had limited success in reducing Aedes populations 20 and, thereby, incidences of 
DENV21, and can instead cause insecticide resistance and behavioral changes such as a shift in 
biting times22,23. Therefore, novel vector control strategies24, like the use of genetically modified 
mosquitoes to either suppress mosquito populations or render mosquitoes unable to transmit 
pathogens25, are increasingly needed. For example, the development and deployment of a genetic 
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Sterile Insect Technique (SIT)-like system termed Release of Insect Dominant Lethal (RIDL) has 
had some success in reducing Aedes mosquito populations in the wild26,27. Moreover, releases of 
mosquitoes artificially infected with the intracellular endosymbiont Wolbachia, which can make 
infected males incapable of successfully mating with uninfected females in an SIT-like manner 
and can inhibit mosquito infection with pathogens such as DENV and ZIKV28,29, have also been 
carried out to either suppress mosquito populations or make them less likely to transmit pathogens, 
and may hold promise for reducing incidence of disease30,31. However, these technologies require 
releases of large numbers of insects - and must be carried out on an ongoing basis for RIDL and 
Wolbachia-based SIT - for continued vector control, which is laborious and expensive.  
Therefore, there has been increasing interest in the development of engineered gene-drive 
technologies, which are able to rapidly transmit themselves and any linked “cargo” genes, such as 
anti-pathogen effectors, through wild disease-transmitting populations25,32,33 such that only a few 
releases of modest amounts of engineered insects could drive desirable cargo genes through wild 
populations, making them efficient and cost effective for vector control. To achieve disease 
reduction, such gene-drive systems need to be linked to useful “cargo”, such as effective anti-
pathogen genes, and several approaches for engineering Ae. aegypti resistance to DENV have been 
attempted. For example, one study used RNA interference by employing inverted RNA repeats to 
target DENV-2 in a conditional and tissue-specific manner34,35, while another described miRNA 
cassettes targeting DENV-3 that reduced viral transmission rates36. In addition to using synthetic 
small RNAs, others have taken advantage of the mosquito’s innate antiviral JAK/STAT pathway 
to increase resistance to DENV-2 and DENV-437. However, all previous approaches have been 
limited by their ability to target only one or two—not all four—major DENV serotypes. Because 
hyperendemicity of DENV in tropical areas is frequent5 and secondary DENV infection has been 
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linked to severe dengue disease (SDD), refractory mosquitoes should be capable of blocking all 
serotypes or risk being ineffective in controlling dengue epidemics. Therefore, better anti-DENV 
effectors are needed. 
Broadly neutralizing antibodies may be especially promising as anti-DENV effector gene 
candidates because of their ability to neutralize antigenically diverse viruses38. However, while 
engineered monoclonal antibodies that confer resistance to Plasmodium, a protozoan parasite that 
causes malaria, have been expressed in Anophelene mosquitoes39–41, none targeting a virus have 
been described in any mosquito species. Previously, a DENV-targeting 1C19 monoclonal antibody 
(MAb) was identified from a large panel of naturally occurring MAbs from human subjects 
following vaccination or natural infection42. In vitro studies demonstrated that this antibody 
neutralized viruses from all major DENV serotypes and was capable of significantly reducing 
viremia in a mouse model after DENV-1 and DENV-2 infection42. Here, we engineer Ae. aegypti 
to express a 1C19-based, broadly neutralizing, single-chain variable fragment (scFv) that is 
capable of neutralizing all four DENV serotypes42. Crucially, we demonstrate that mosquitoes 
expressing this anti-DENV scFv cannot be infected with or transmit any of the four DENV 
serotypes and have few significant fitness costs conferred by the presence of the antibody. These 
results provide a promising route for developing effective DENV control strategies using 
genetically engineered mosquitoes.  
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Results 
Generation of DENV-resistant mosquitoes 
To determine whether expressing an anti-DENV antibody in mosquitoes could confer 
resistance to DENV, we first needed to engineer a broadly neutralizing antibody that was 
compatible with mosquitoes and could be expressed in vivo in its desired form. We chose 1C19 as 
our model due to its ability to cross-neutralize multiple DENV serotypes in humans42. As it is a 
human monoclonal antibody, however, it cannot be unobtrusively expressed in mosquitoes, so a 
new form that is both compatible with mosquitoes and maintains its neutralization capabilities had 
to be designed. We then choose to engineer an scFv comprising the linked variable heavy (VH) 
and light (VL) chains because this format removes the human-specific constant region that could 
impart difficulties in a mosquito and it can be expressed in one “chunk” in an organism without 
the need for additional in vivo processing. To do this, sequences for the 1C19 VH and VL chains 
were obtained from hybridoma cells expressing the human monoclonal antibody42. We then 
engineered a scFv comprising the VH and VL domains of 1C19 linked using a 15-amino-acid 
repeating glycine-serine  [G(4)S]3 linker43 that was codon-optimized for Ae. aegypti. We also 
engineered a version of this 1C19 scFv that was fused with a 3’ 30-amino-acid human influenza 
hemagglutinin (HA) epitope tag, commonly used as a general expression tag, reasoning that it 
might be useful in downstream expression analyses. To conditionally drive expression of the 1C19 
scFvs in the midgut of female mosquitoes following a blood meal, which would ensure 1C19 
expression any time the mosquito was in contact with DENV, we used the Ae. aegypti 
carboxypeptidase (CP) promoter44 that induces expression in the midgut following blood ingestion 
(Figure 1A). The engineered anti-DENV transgenes (termed plasmid OA984 for the untagged 
version and plasmid OA984-HA for the HA-tagged version) also contained an eye-specific 3xP3 
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promoter45, driving expression of tdTomato as a fluorescent transgenesis marker. Following the 
typical transgenesis procedure in mosquitoes, consisting of embryonic microinjection and G0 
outcrossing, multiple independent transgenic lines (n = 6) were readily identified in the G1 
generation via the robust expression of tdTomato fluorescence; three of the lines with the strongest 
marker expression (termed Transgenic Anti-DENV [TADV]-A, containing OA984; and TADV-B 
and C, containing OA984-HA) were selected for further experiments. We carried out inverse PCR 
(iPCR) on genomic DNA extracted from the transgenic mosquitoes to verify the transgene 
insertion site and performed backcrosses to WT for multiple generations to ensure that the 
transgenic lines represented single chromosomal insertions, and were able to confirm that,  in all 
three independent lines, the anti-DENV transgenes were stably integrated into single 
chromosomes.  
 
Expression of 1C19 scFv antibody 
Robust expression and processing of 1C19 scFv transcripts is required for proper 
neutralization of DENV, and it is important to know if such expression perturbs global gene-
expression patterns, which might interfere with the fitness of the mosquito. To confirm this, we 
sequenced total RNA populations from dissected midgut tissues isolated from both blood-fed and 
non-blood-fed female Higgs wildtype (WT) or TADV-A, B, or C mosquitoes using an Illumina 
platform. We detected robust expression of the 1C19 scFv mRNA in both non-blood-fed and 24-
hour post-blood-fed transgenic mosquitoes of all three lines, with clearly increased expression 
levels at 24-hours post-blood meal, while no expression was observed in the midguts of female 
WT mosquitoes, suggesting that expression of the 1C19 scFv antibody is transgene-dependent and 
blood-meal-inducible (~2.35-14.45 fold) as was intended. Importantly, there appeared to be no 
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major shifts in global gene expression patterns between WT and TADV mosquitoes, suggesting 
that the 1C19 scFv expression did not globally affect gene-expression patterns (Figure S1, 
Supplementary Table S4).   
To confirm the proper expression of the 1C19 scFv, we performed western blots on 
dissected midgut tissue from non-blood-fed and blood-fed WT and TADV-A as well as blood-fed 
TADV-B and TADV-C female mosquitoes using either a custom anti-1C19 scFv antibody, or an 
anti-HA antibody. Blot analyses revealed that the 1C19 scFv peptide was efficiently expressed 
following a blood meal exclusively in transgenic mosquitoes (Figure S2). Altogether, these results 
suggest that the anti-DENV transgene is stably integrated into the mosquito genome and that the 
DENV-targeting 1C19 antibody is expressed in an appropriate context (i.e., in the midgut 
following a blood meal) for DENV suppression. 
 
Engineered mosquitoes are resistant to infection with all four DENV serotypes 
To determine the functional significance of anti-DENV 1C19 scFv expression on vector 
competence, the DENV-2 infection rates of the three transgenic TADV lines were first compared 
to that of WT. To do this, adult females (WT or TADV-A, B, or C) were exposed to serotype 
DENV-2 (isolate ET300, Genbank EF440433) via membrane blood feeding. At 4 days post 
infection (dpi), midguts from blood-fed mosquitoes were dissected, and DENV RNA copies were 
measured using RT-qPCR. All three lines showed a significant reduction in midgut infection rate 
(45 to 71%) and viral RNA levels (2 to 3 log lower) compared with WT control mosquitoes 
(infection rate 92%) (Figure S3; Table S1). Since no significant difference in DENV-2 midgut 
infection levels was detected between the three transgenic lines, TADV-A, which exhibited the 
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strongest antiviral phenotype (Figure S3; Table S1), was selected for further comprehensive 
characterization. 
For a more detailed study of the TADV-A DENV vector competence, the effect of 
transgene zygosity on the infection rate was determined by exposing additional adult females (WT 
or TADV-A) to serotype DENV-2 and analyzing the dissected midguts at 4 dpi. Results from three 
biological replicates revealed that none of the TADV-A mosquitoes homozygous for the transgene 
(n = 35) were positive for DENV-2 infection in the midguts (Figure 1B). DENV-2 infection was 
detected in 85.4% (35/41) of the TADV-A mosquitoes that were heterozygous for the transgene; 
however, these mosquitoes had significantly (p < 0.001) lower (~3 log10) viral RNA levels 
(8.20 x 101 genome equivalent [GE]) than the WT (4.25 x 104 GE) (Figure 1B, Table 1). 
To assay for viral dissemination to the rest of the mosquito body, total RNA was collected 
from whole TADV-A mosquito carcasses (without midguts) and dissected midguts from both 
homozygous and heterozygous mosquitoes at 14 dpi. The results from three biological replicates 
indicated that none of the homozygous TADV-A mosquitoes (n = 30) were positive for viral 
replication (dissemination) in either the midgut or the midgut-free carcass (Figure 1B, Table 1). 
DENV-2 prevalence was detected in 86.6% (26/30) of heterozygous TADV-A mosquitoes in both 
the carcass and midgut; however, they also had significantly (p < 0.001) lower levels of viral RNA 
(~3 log10) compared to the WT (Figure 1B, Table 1). Finally, as transmission occurs through the 
saliva, viral transmission rates were determined by collecting the saliva from individual 
mosquitoes at 14 dpi and measuring the DENV-2 titers using an assay for the median tissue culture 
infective dose (TCID50). No DENV-2 was detected in the saliva of homozygous TADV-A 
mosquitoes (n = 30) (Figure 1B), though it was detected in 83.3% (25/30) of heterozygous TADV-
A mosquitoes; however, here again the DENV-2 titers were significantly (p < 0.001) lower 
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(3.56 x 102 TCID50/ml/mosquito) than the WT mosquitoes (2.70 x 105 TCID50/ml/mosquito) 
(Figure 1B, Table 1). 
To determine whether the anti-DENV 1C19 scFv is broadly inhibitory for other DENV 
serotypes, the vector competence of TADV-A mosquitoes was assessed using DENV-1 (isolate 
ET243, GenBank EF440432), DENV-3 (isolate ET209, Genbank EF440434), and DENV-4 
(isolate ET288, Genbank EF440435). Tests for infection, dissemination, and transmission were 
carried out as above, and the results, presented together in Figure 1B and Table 1, were comparable 
to those obtained with the DENV-2 serotype. In short, the TADV-A mosquitoes homozygous for 
the transgene proved to be refractory to infection with all three additional serotypes also showing 
no infection in their midguts at 4 dpi (DENV-1 n = 28; DENV-3 n = 30; DENV-4 n = 27). Even 
at 14 dpi, there was no sign of viral replication in the midgut or carcass for all tested specimens, 
and none of the saliva samples (DENV-1 n = 28; DENV-3 n = 30; DENV-4 n = 28) were positive 
for the virus. As with DENV-2, the mosquitoes heterozygous for the transgene still tested positive 
for the virus in most specimens, though the overall DENV titers were significantly lower than 
compared to the WT in all cases (Figure 1B; Table 1). 
 
Engineered anti-DENV mosquitoes outperform Wolbachia  
To compare the inhibitory effect of the anti-DENV 1C19 scFv to DENV inhibition through 
Wolbachia47–49 infection, we challenged WT mosquitoes infected with Wolbachia (wMel) with 
DENV-2. Vector competence results revealed that midguts from mosquitoes infected with 
Wolbachia had significantly (p < 0.001) reduced DENV-2 RNA levels (4.75 x 101 GE) at 4 dpi 
compared with the WT (4.25 x 104 GE) (Figure 2A, Table 1). Similarly, viral dissemination at 14 
dpi was also reduced (p < 0.001) in wMel mosquitoes (~3 log10), and DENV titers in mosquito 
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saliva at 14 dpi were significantly (p < 0.01) lower (~3 log10) in wMel mosquitoes (4.90 x 101 
TCID50/ml/mosquito) than in the WT (2.70 x 105 TCID50/ml/mosquito) (Figure 1B, Table 1). 
Importantly, a direct comparison  revealed that the TADV-A mosquitoes are significantly 
(p < 0.001) more effective as homozygotes, and similarly effective as heterozygotes, at blocking 
DENV infection as Wolbachia-infected mosquitoes.  
 
Transgene impact on fitness  
To determine whether the anti-DENV 1C19 scFv had any significant fitness effects on 
transgenic mosquitoes, we assessed several fitness parameters including larval to pupal 
development time, male and female fecundity and fertility, male mating success, and longevity 
(Table 2). No significant differences were observed between WT and TADV-A mosquitoes when 
examining male mating success and fecundity and fertility in both males and females (p > 0.05). 
However, we noticed a significant difference in larval to pupal development times (p < 0.0001), 
with WT mosquitoes developing, on average, 0.8 days faster than TADV-A mosquitoes. When 
assessing mosquito survivorship, there was no significant difference between WT and TADV-A 
males (p > 0.05; Figure S4), though, WT female mosquitoes lived, on average, 4.5 days longer 
than TADV-A females (p < 0.05; Figure S4). The longevity of infected mosquitoes was also 
assessed. Transgenic, WT, or wMel mosquitoes were infected with four DENV serotypes and their 
survivorship was assessed 14 dpi (Table 2). No significant (p > 0.01) differences between WT and 
TADV-A longevity upon infection with serotypes DENV-2, -3, and -4 were observed. However, 
there was a significant difference in survival upon infection with serotype DENV-1, with a higher 
proportion of WT mosquitoes surviving at 14 dpi (p < 0.01; Table 2, Figure S4). In addition, a 
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significant difference in survival between wMel mosquitoes and WT and TADV-A mosquitoes 
infected with serotype DENV-2 was observed (p < 0.0001; Figure S4).  
 
Discussion 
Our results demonstrate that conditional expression of the anti-DENV 1C19 scFv renders 
mosquitoes refractory to all four major DENV serotypes and therefore appears to be a potent viral 
inhibition strategy. While mosquitoes homozygous for the anti-DENV 1C19 scFv showed 
complete refractoriness to DENV infection, heterozygous mosquitoes were still partially refractory 
to DENV infection, dissemination, and transmission, with significant, several orders-of-magnitude 
reductions in viral titers in the saliva. Based on previous findings, it is likely that this significant 
reduction in viral titers would be sufficient to render heterozygous mosquitoes unable to transmit 
DENV to a susceptible host50. Though this remains to be demonstrated, our results show that 
heterozygous 1C19 scFv antibody-expressing transgenic mosquitoes are just as efficient at viral 
suppression as—and homozygous mosquitoes are significantly more efficient than—Wolbachia-
infected mosquitoes, which are currently being released for DENV control because they are known 
to be refractory to DENV47.  
The difference in refractory levels in the homozygous versus heterozygous mosquitos also 
suggests that the refractory phenotype is particularly sensitive to scFv antibody expression levels, 
a phenomenon previously observed with anti-malarial scFv transgenes 39 and anti-ZIKV synthetic 
small RNA transgenes 51. If this means that complete refractoriness is susceptible to positional 
effects, e.g., not refractory when the scFv antibody transgene is expressed from a different, 
possibly more weakly expressing genomic insertion position, the identification of more robust 
midgut-specific promoters may help to ensure sufficiently high expression levels from a single 
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copy of the transgene regardless of insertion site, as can the use of multiple anti-DENV scFv 
antibodies in a single transgene 39,41.  
The strategy we describe here provides an efficient “cargo” gene that can be coupled with 
a gene-drive system to reduce or eliminate the risk of DENV transmission by mosquitoes. Given 
the success of previous efforts to develop Cas9-mediated homing-based gene drives in Anopheles 
stephensi52, the malaria vector, it should be possible to develop such drives in Ae. aegypti. 
Additionally, since homing-based drive systems quickly convert heterozygotes to homozygotes 25, 
linking the anti-DENV 1C19 scFv antibody described here to such a drive system could, in theory, 
rapidly convert wild mosquito populations into transgenic homozygotes that would be completely 
resistant to DENV transmission. Of paramount importance to the viability of such an approach is 
the evolutionary stability of the refractory transgene, specifically in terms of the likelihood of viral-
resistant evolution. Indeed, several studies have shown that, in some contexts, DENV can rapidly 
evolve resistance in response to neutralizing antibodies53,54, although this can be managed through 
the selection of antibodies with mechanisms/epitopes that minimize the chance of evolved 
resistance and the use of a combination of distinct anti-DENV antibodies, many of which have 
been described (e.g.,42,53–56). The deployment of such a pan-serotype-targeting strategy could serve 
as an effective component of a comprehensive program to reduce the incidence and impact of 
DENV. 
Due to similarities within viral families, this research could have far-reaching 
consequences for rendering mosquitoes resistant to other arboviruses like ZIKV and CHIKV by 
using similar genetic engineering strategies to develop scFv-based transgenes. Multiple potent 
antibodies that effectively neutralize these various mosquito-borne viruses have also been 
identified in the last decade57–61. Although not all of these will confer robust viral resistance when 
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expressed in vivo in mosquitoes, the availability of diverse, well-characterized antibodies of this 
sort, largely as a result of antibody therapeutic development efforts58, should allow for the 
identification of those that function within the desired context. Given the increasing incidence of 
disease caused by these viruses and the resulting global health implications, such scFv-based 
transgenes (coupled with gene-drive systems) can provide an effective, sustainable, and 
comprehensive strategy for reducing the impact of arboviral mosquito-borne diseases. 
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Materials and Methods 
 
Anti-DENV scFv design 
Sequences for the 1C19 variable heavy and light chains were obtained from hybridoma cells 
expressing the human monoclonal antibody 42 that had been cloned biologically by flow cytometry. 
RNA was extracted using the RNeasy kit (Qiagen #74104), and RT-PCR amplification of antibody 
gene cDNAs was performed using primer sets designed to detect all human antibody variable gene 
sequences 42. The sequence of the antibody cDNAs was determined by automated Sanger sequence 
analysis. The sequence analysis of the antibody variable gene sequences in the cDNAs was 
performed using the international ImMunoGeneTics information system (IMGT).  
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The variable regions of 1C19 were joined by a 15-amino-acid repeating glycine-serine  [G(4)S]3 
linker43 to encode a scFv form of the antibody62. These chain regions were codon optimized for 
Ae. aegypti expression and then gene synthesized into a vector (GenScript, Piscataway, NJ). For 
OA984-HA, a 3’ 30-amino-acid human influenza hemagglutinin (HA) epitope tag with a G(4)S 
linker63 was added to the carboxy terminus of the single chain antibody for protein expression 
verification.  
 
Plasmid assembly 
To generate vector OA984 (the anti-DENV scFv-antibody transgene), several components were 
cloned into the PiggyBac plasmid pBac[3xP3-DsRed] (a kind gift from R. Harrell) using Gibson 
assembly/enzymatic assembly (EA) cloning 64. First, a Drosophila codon-optimized tdTomato 
marker was amplified with primers 984.1A and 984.1B (Supplementary Table S2 for all primers) 
from a gene synthesized vector (GenScript, Piscataway, NJ) and cloned into a XhoI/FseI-digested 
pBac[3xP3-DsRed] backbone using EA cloning. The resulting plasmid was digested with AscI, 
and the following components were cloned in via EA cloning: the predicted Ae. aegypti 
carboxypeptidase promoter 44 amplified from Ae. aegypti genomic DNA using primers 984.2A 
and 984.2B, a GFP sequence amplified from vector pMos[3xP3-eGFP] 65 with primers 984.3A 
and 984.3B, and a 677-bp p10 3’ untranslated region (UTR) amplified with primers 984.4A and 
984.4B from vector pJFRC81-10XUAS-IVS-Syn21-GFP-p10 (Addgene plasmid #36432). The 
anti-DENV scFv was then subcloned into the final vector from a gene-synthesized plasmid 
(GenScript, Piscataway, NJ) using PmeI and PacI sites and traditional ligation cloning. Annotated 
plasmid sequences and plasmid DNA are available via Addgene (plasmid #120363).  
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To generate vector OA984-HA (anti-DENV scFv with HA-epitope tag), the G(4)S linker and 
HAx3 tag were amplified with primers 984B.C1 and 984B.C2 from the ninaE[SBP-His] vector 
containing these components 66 and cloned into the PacI digested OA984 backbone using EA 
cloning. Annotated plasmid sequences and plasmid DNA are available via Addgene (plasmid 
#120362). All primer sequences used to generate these plasmids are listed in Table S2.  
 
Generation of transgenic mosquitoes  
Germline transformations were carried out largely as described 67. Briefly, 0–1 hr old Higgs 
wildtype (WT) Ae. aegypti pre-blastoderm embryos were injected with a mixture of vector OA984 
or OA984-HA (200 ng/µL) and a source of PiggyBac transposase (200 ng/µL)65; the injected 
embryos were hatched in deoxygenated H2O. A total of 127 surviving WT adult G0 males and 115 
surviving WT adult G0 females were recovered after the injection. Microinjected WT G0 adults 
were assigned to 48 pools and outcrossed to WT of the opposite sex in medium-sized cages. Larvae 
were fed ground fish food (TetraMin Tropical Flakes, Tetra Werke, Melle, Germany) and adults 
were fed with 0.3 M aqueous sucrose. Adult females were blood fed three to five days after 
eclosion using anesthetized mice. All animals were handled in accordance with the Guide for the 
Care and Use of Laboratory Animals as recommended by the National Institutes of Health, and 
the methods were supervised by the local Institutional Animal Care and Use Committee (IACUC). 
A total of 38,177 WT G1s were screened. G1 larvae with strong positive fluorescent signals (3xp3-
tdTomato) were selected under the fluorescent stereomicroscope (Leica M165FC) and were 
separated into six individual groups characterized by fluorescence patterning and intensity. One 
single transgenic male from each group was then allowed to separately mate with 10 WT females 
to isolate each independent line. Three independent lines, TADV-A (vector OA984), TADV-B 
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(vector OA984-HA), and TADV-C (vector OA984-HA) with the strongest fluorescence 
expression patterns were selected for further characterization. To determine whether these lines 
represented single chromosomal insertions, we backcrossed single individuals from each of the 
lines for four generations to WT stock and measured the Mendelian transmission ratios in each 
generation; in all cases, we observed a 50% transmission ratio, indicating single-chromosome 
insertion. For one of the three lines (TADV-A), transgenic mosquitoes were inbred for at least 20 
generations to generate a homozygous stock. Mosquito husbandry was performed under standard 
conditions as previously described 68.  
 
Characterization of insertion sites 
To characterize the insertion site of vector OA984 or OA984-HA in transgenic mosquitoes, we 
adapted a previously described inverse polymerase chain reaction (iPCR) protocol 69 as follows. 
First, genomic DNA (gDNA) was extracted from 10 transgenic fourth instar larvae using the 
DNeasy Blood & Tissue Kit (Qiagen #69504) per the manufacturer’s protocol. Two separate 
restriction digests were performed on the gDNA (at 100 ng/μL) to characterize the 5’ and 3’ ends 
of the PiggyBac insertion using Sau3AI (5’ reaction) or HinP1I (3’ reaction) restriction enzymes. 
A ligation step using NEB T4 DNA Ligase (NEB #M0202S) was performed on the restriction 
digest products to circularize digested gDNA fragments, and two subsequent rounds of PCR were 
carried out per ligation using the corresponding PiggyBac primers listed in Supplementary Table 
S3. The final PCR products were cleaned up using the MinElute PCR Purification Kit (Qiagen 
#28004) in accordance with the manufacturer’s protocol and were sequenced via Sanger 
sequencing (Source BioScience, Nottingham, UK). To confirm the transgene insertion locus and 
orientation via PCR, primers were designed based on iPCR-mapped genomic regions and used in 
.CC-BY-NC-ND 4.0 International licenseIt is made available under a 
(which was not peer-reviewed) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
The copyright holder for this preprint. http://dx.doi.org/10.1101/645481doi: bioRxiv preprint first posted online May. 24, 2019; 
 19 
tandem with PiggyBac primers based on their location as listed in Supplementary Table S3. 
Sequencing data then was blasted to the AaegL5.0 reference genome 70. The sequencing data was 
aligned with SeqManPro (DNASTAR, Madison, WI) to determine the orientation of the transgene 
insertion site. Analysis of the sequencing data indicated that the insertion site for TADV-A is on 
chromosome 2 (approximate position 310,340,476), the insertion site for TADV-B is on 
chromosome 2 (approximate position 301,489,980), and the insertion site for TADV-C is on 
chromosome 1 (approximate position 30,451,048) when aligned to the AaegL5 assembly 
(GenBank assembly accession: GCA_002204515.1)46. 
 
Total RNA extraction, isolation, and sequencing 
Total RNA was extracted from the midguts of non-blood-fed and 24-hours post-blood-fed TADV-
A, TADV-B, TADV-C or WT adult females using the Ambion mirVana mRNA Isolation Kit 
(ThermoFisher Scientific #AM1560). Following extraction, the RNA was treated with Ambion 
Turbo DNase (ThermoFisher Scientific #AM2238). The RNA quality was assessed using an RNA 
6000 Pico Kit for Bioanalyzer (Agilent Technologies #5067-1513) and a NanoDrop 1000 UV-vis 
spectrophotometer (NanoDrop Technologies/Thermo Scientific, Wilmington, DE). mRNA was 
isolated using an NEBNext Poly(A) mRNA Magnetic Isolation Module (NEB #E7490), and 
libraries were constructed using an NEBNext Ultra II RNA Library Prep Kit for Illumina (NEB 
#E7770). The libraries were quantified using a Qubit dsDNA HS Kit (ThermoFisher Scientific 
#Q32854) and a High Sensitivity DNA Kit for Bioanalyzer (Agilent Technologies #5067-4626) 
and sequenced on an Illumina HiSeq2500 in single-read mode with a read length of 50 nt and 
sequencing depth of 30 million reads per library following the manufacturer's instructions. Reads 
were mapped to the Ae. aegypti genome (AaegL5.0) supplemented with the 1C19 cDNA sequence 
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using STAR aligner 71, and the expression levels were determined with featureCounts 72 
(Supplementary Table S4). Correlation coefficients of the transcripts-per-million (TPM) values 
between WT and transgenic animals were calculated in R[14] and plotted with ggplot2 (Figure 
S1). All sequencing data can be accessed at NCBI SRA (study accession ID PRJNA510258). 
 
Western blot assays 
The general western blot protocol was adapted from CSH Protocols: SDS-PAGE of Proteins 74. 
Briefly, 5–7 days post eclosion, midguts from 25 non-blood-fed and 16-hour post-blood-meal 
heterozygous TADV-A transgenic and WT mosquitoes were dissected and collected in 1x PBS. 
Protein samples from dissected tissues were extracted with ice-cold radioimmunoprecipitation 
assay buffer (RIPA buffer; 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.25% Na-deoxycholate, 1% 
NP-40, 1 mM EDTA). The protein concentration was measured using Protein Assay Dye (Bio-
Rad, Cat. No#5000006) and multi-detection microplate readers (Molecular Devices, SpectraMax 
M2). Next, 40 µg of total protein were run on a 12% SDS-PAGE and transferred onto a 0.45 µm 
Immobilon®-P Transfer Membrane (Merck Millipore, Cat. NO#IPVH00010). The membrane was 
hybridized with a custom antibody at a 1 µg/mL dilution (GenScript, Item number: 
U3233DA170_2) to directly recognize the 1c19 scFv peptide (26.3KDa) as well as a monoclonal 
antibody specific to the HA tag for lines TADV-B and C (Cell Signaling, #3724S) at a 1:1,000 
dilution; these were subsequently detected by using rabbit IgG antibody (HRP) (GeneTex, Cat. 
No#GTX 213110-01) at a 1:10,000 dilution. Images were generated by applying the 
chemiluminescent HRP substrate (Millipore, Cat. No#WBKLS0500) to the blots. 
 
DENV infection of mosquitoes and virus determination 
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All experiments were performed under biosafety level 3 (BSL-3) conditions in the insectary at the 
Australian Animal Health Laboratory. The following DENV strains were used for all viral 
challenge experiments: DENV-1 (isolate ET243, GenBank EF440432), DENV-2 (isolate ET300, 
GenBank EF440433), DENV-3 (isolate ET209, GenBank EF440434), DENV-4 (isolate ET288, 
GenBank EF440435). The virus was passaged in Vero cell monolayer cultures before use for 
mosquito infections. WT or transgenic (confirmed by red fluorescence in the eye) mosquitoes were 
exposed to DENV as described previously 75. Briefly, female mosquitoes were challenged with an 
infected blood meal (TCID50 /mL) through membrane feeding using chicken blood and skin. For 
infection frequency and virus titer, mosquito midguts were collected at 4 dpi. For dissemination 
and transmission frequency, mosquito saliva, midguts, and carcasses were collected at 14 dpi. 
Mosquito saliva was used to determine viral titers using a TCID50 assay on Vero cell monolayer 
cultures. Midguts and carcasses were used to determine the presence of viral RNA using RT-qPCR 
against NS5. Mosquito viral challenge, processing, saliva testing, and molecular analyses of 
infection and dissemination were carried out as previously described 75. DENV infection frequency 
was defined by the number of midguts (day 4) found positive for viral nucleic acid. Similarly, the 
dissemination frequency was calculated by the number of carcasses (day 14) found positive by 
qPCR. Transmission frequency was defined by the number of TCID50-positive saliva samples over 
the number tested. These different frequencies and average TCID50 values were compared by the 
Student’s two-tailed t-test. 
 
Confirmation of transgene zygosity 
Both homozygous and heterozygous (generated by crossing out homozygous individuals to WT) 
mosquitoes were used for assays. To confirm the zygosity of tested transgenic mosquitoes, 
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mosquito heads were homogenized using a bead-beater device for DNA extraction in 30 μL of 
extraction buffer (1x Tris-EDTA, 0.1 M EDTA, 1 M NaCl, and 2.5 μM proteinase K) and 
incubated at 56°C for 5 minutes and then at 98°C for 5 minutes. The first round of PCR was 
performed to test for the presence of the anti-DENV transgene using primers 991.3F1 and 
1018.S19 (Supplementary Table S3). Another round of PCR then was performed using primers 
1018.S19 and 1018.S21 (Supplementary Table S3) to amplify the WT insertion locus (i.e., locus 
lacking transgene insertion) and thus determine zygosity. For TADV-B, primer set 991.3R2 and 
1018.S73 was used to amplify the anti-DENV transgene and primer set 1018.S73 and 1018.S74 
were used to amplify the WT insertion site. For TADV-C, primer sets 991.3F2 and 1018.S80 and 
set 1018.S80 and 1018.S82 were used to amplify the anti-DENV transgene and WT insertion site, 
respectively. WT mosquitoes served as controls to ensure that the WT locus was successfully 
amplified in the genetic background. A PCR kit (ThermoFisher Scientific #F553S) with a 57°C 
annealing temperature was used for all PCRs following standard protocols. 
 
Generation of wMel Wolbachia Line and Infection Assay 
Eggs of Ae. aegypti infected with the Wolbachia strain wMel were obtained from the World 
Mosquito Program (Prof. Scott O’Neill, Monash University). WT mosquitoes infected with wMel 
were generated by crossing wMel+ females with males from the WT line, and the resulting 
offspring were used for DENV infection experiments. At the end of the experiment, the Wolbachia 
infection status of these mosquitoes was tested using PCR with primers specific for wMel detection 
76 (Supplementary Table S3). The PCRs indicated the presence of wMel in >90% of mosquitoes, 
and only results from these positive mosquitoes were used for further analysis. 
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Fitness evaluation on transgenic anti-DENV mosquitoes 
To determine if the anti-DENV transgene conferred a fitness cost, several fitness parameters were 
evaluated in TADV-A transgenic heterozygous and sibling WT mosquitoes. The evaluations of all 
experimental and control replicates were performed simultaneously. Insectary conditions were 
maintained at 28℃ and 70 to 80% in relative humidity with a 12 hr light/dark cycle. To assess the 
larval to pupal development time, the eggs were vacuum hatched, and the larvae were distributed 
into pans (50 larvae per pan) containing 2.5 L of ddH2O and 0.6 mL of fish food slurry. To 
determine the larval to pupal development time of transgenic and WT control mosquitoes, the 
larvae were allowed to pupate, and pupae were collected and counted every day until no pupae 
were left. To assess female fertility and fecundity, 90 WT and transgenic females were mated to 
20 WT males in a cage. After four days, the females were blood fed and individually transferred 
into plastic vials filled with water and lined with egg paper. After three days, egg papers were 
collected, and the eggs were counted and vacuum hatched in nine-ounce plastic cups. Starting on 
the fourth day, the larvae were counted every day until no larvae were present. Female fecundity 
refers to the number of eggs laid per female, and fertility reflects the number of eggs hatching to 
produce larvae. To measure male mating success, fecundity, and fertility, one TADV-A transgenic 
or WT male was mated to five WT females in a single mesh-covered cup filled with water and 
lined with egg paper. Three days post blood meal, the cups were checked for the presence of eggs, 
which were collected, counted, and hatched. Hatched larvae were then counted every day until no 
larvae were present. Male mating success was calculated as the percentage of single male 
outcrosses that produced larvae. Fecundity was measured as the number of eggs laid per cup; 
fertility was determined by the number of hatching larvae in each cup. Finally, to assess mosquito 
longevity, equal numbers of male and female TADV-A transgenic or WT mosquitoes were placed 
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in medium-sized cages (in triplicate). Mosquitoes that died were counted and removed daily until 
all mosquitoes had died. Statistical analyses were performed using GraphPad Prism software 
(GraphPad Software, La Jolla, California, USA). The means were compared using unpaired t tests 
with Welch’s correction, with the exception of male mating success that did not use Welch’s 
correction. The analyses of mosquito survivorship used the Mantel-Cox test. P values > 0.05 were 
considered not significant.  
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Figure 1. Effect of anti-dengue virus (DENV) single-chain variable fragment (scFv) on DENV 
titers of TADV-A, Wolbachia-infected (wMel), and wildtype (WT) mosquitoes. (A) Schematic of 
experiment. TADV-A mosquitoes were generated via transgenesis with the anti-DENV construct, 
and TADV-A, wMel, and WT mosquitoes were then challenged with a blood meal infected with 
one of four DENV serotypes (DENV-1, isolate ET243; DENV-2, isolate ET300; DENV-3, isolate 
ET209; or DENV-4, isolate ET288). After the infected blood meal enters the mosquito midgut, 
there are two potential outcomes: in the first (applies for all tested strains), the virus replicates and 
disseminates past the midgut to become transmissible; in the second (applies to TADV-A 
mosquitoes), the anti-DENV transgene expresses scFv antibodies in the midgut that bind to the 
virus and neutralize it. (B) Plots depicting viral titers. To determine if the anti-DENV transgene 
confers resistance to all four DENV serotypes, we determined viral titers in extracted midguts, 
carcasses, and saliva from WT, TADV-A (homozygous [Hm] and heterozygous [Ht]), and wMel 
infected mosquitoes. Viral genome equivalents (GE) from mosquito midguts (at 4 days post 
infection [dpi]) and carcass (at 14 dpi) were determined using RT-qPCR and calculated using 
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previously published methods. Viral titers in the saliva were determined using the median tissue 
culture infective dose (TCID50) on Vero cells. For each experiment, data from three replicates is 
pooled. Red horizontal bars represent the mean GE/viral titer. **p < 0.001. 
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Table 1. Anti-DENV scFv effect on DENV infection, dissemination, and transmission rates. 
DENV titers in WT, heterozygous and homozygous TADV-A (TADV-AHt and TADV-AHm, 
respectively), and wMel mosquitoes following a blood meal infected with one of four DENV 
serotypes are shown. DENV GE from mosquito midguts (at 4 or 14 dpi) and carcasses (14 dpi) of 
WT, TADV-A, and wMel (for DENV-2 only) mosquitoes were determined using RT-qPCR and 
calculated using previously published methods. Viral titers in saliva collected from WT,  TADV-
A, and wMel mosquitoes at 14 dpi were determined using TCID50 on Vero cells.  
  
DENV GE or viral titer on indicated dpi from specified tissue 
(proportion of mosquitoes with detected virus ; percentage of mosquitoes with detected virus ) 
  
 DENV 
Serotype 
 
 
 Strain 
4 dpi 14 dpi 
Midgut– 
GE 
Midgut– 
GE 
Carcass– 
GE 
Saliva– 
viral titer 
  
  
 
DENV-1 
WT 5.70 x 103 
(29/35; 83%) 
3.80 x 105 
(35/40; 88%) 
4.80 x 105 
(35/40; 88%) 
3.04 x 105 
(35/40; 88%) 
TADV-AHt 5.00 x 101 
(20/28; 71%) 
3.70 x 102 
(25/30; 83%) 
2.40 x 102 
(25/30; 83%) 
2.50 x 102 
(25/30; 83%) 
TADV-
AHm 
0.00 x 101 
(0/28; 0%) 
0.00 x 101 
(0/28; 0%) 
0.00 x 101 
(0/28; 0%) 
0.00 x 101 
(0/28; 0%) 
  
  
  
 
DENV-2 
WT 4.25 x 104 
(34/40; 85%) 
4.40 x 105 
(40/46; 87%) 
5.35 x 105 
(40/46; 87%) 
2.70 x 105 
(38/46; 83%) 
TADV-AHt 8.20 x 101 
(35/41; 
85.4%) 
3.90 x 102 
(26/30; 
86.6%) 
6.70 x 102 
(26/30; 87%) 
3.56 x 102 
(25/30; 83.3%) 
wMel 4.75 x 101 
(43/48; 90%) 
5.10 x 101 
(38/48; 79%) 
6.45 x 101 
(38/48; 79%) 
4.90 x 101 
(35/48; 73%) 
TADV-
AHm 
0.00 x 101 
(0/35; 0%) 
0.00 x 101 
(0/30; 0%) 
0.00 x 101 
(0/30; 0%) 
0.00 x 101 
(0/30; 0%) 
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DENV-3 
WT 1.80 x 104 
(23/30; 77%) 
2.90 x 105 
(29/35; 83%) 
3.50 x 105 
(29/35; 83%) 
2.90 x 105 
(29/35; 83%) 
TADV-AHt 3.60 x 101 
(22/30; 73%) 
1.58 x 102 
(20/30; 66%) 
1.60 x 102 
(20/30; 67%) 
1.33 x 102 
(20/30; 67%) 
TADV-
AHm 
0.00 x 101 
(0/30; 0%) 
0.00 x 101 
(0/30; 0%) 
0.00 x 101 
(0/30; 0%) 
0.00 x 101 
(0/30; 0%) 
  
  
 
DENV-4 
WT 3.25 x 103 
(25/30; 83%) 
3.80 x 104 
(25/32; 78%) 
1.50 x 105 
(25/32; 78%) 
1.60 x 105 
(25/32; 78%) 
TADV-AHt 3.40 x 101 
(22/30; 73%) 
2.38 x 102 
(19/28; 68%) 
2.95 x 102 
(19/28; 68%) 
1.08 x 102 
(19/28; 68%) 
TADV-
AHm 
0.00 x 101 
(0/27; 0%) 
0.00 x 101 
(0/28; 0%) 
0.00 x 101 
(0/28; 0%) 
0.00 x 101 
(0/28; 0%) 
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Table 2. Effect of anti-DENV scFv on fitness. Comparisons of several fitness parameters (left-
most column) between WT (second column from left) and TADV-A mosquitoes (third column 
from left) suggest that there are few significant differences (right-most column) between the two 
groups, indicating that the anti-DENV scFv does not have a major impact on mosquito fitness. The 
survivorship of infected and non-infected mosquitoes is also shown. The median survival in days 
was determined for non-infected mosquitoes, and the percent of surviving mosquitoes separately 
infected by four DENV serotypes was assessed at 14 dpi.  
 
 Strain  
Fitness Parameter 
WT 
(N) 
TADV-A 
(N) P-value  
Female fecundityᶿ†§ 103.6 ± 3.8 (60; 6,213) 110.2 ± 4.4 (57; 5,756) 0.2578 
Egg hatchabilityᶿǁ§ 67.5 ± 3.2 (60; 4,208) 61.0 ± 4.1 (57; 4,046) 0.2149 
Male mating successᶿο¶ 93.00 ± 0.04 (43) 95.00 ± 0.04 (37) 0.7756 
Male fecundityᶿl§ 226.3 ± 15.7 (43; 
9,730) 
202.7 ± 17.2 (37; 7,318) 0.3141 
Egg hatchabilityᶿⅢ§ 75.9 ± 4.5 (43; 7,558) 73.1 ± 3.9 (37; 5,624) 0.6260 
Larval to pupal development 
in daysᶿ§ 
6.70 ± 0.77 (1,322) 7.50 ± 0.09 (774) <0.0001 
Female median survival in 
days†† 
53 (122) 48.5 (128) 0.0129 
Male median survival in 
days†† 
14 (175) 14 (184) 0.1781 
% Survival at 14 dpi with 
DENV-1‡††  
80.8 (26) 43.5 (23) 0.0086 
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% Survival at 14 dpi with 
DENV-2‡††  
72.7 (33) 69.2 (34) 0.6891 
% Survival at 14 dpi with 
DENV-3‡††  
64.9 (37) 52.2 (46) 0.2679 
% Survival at 14 dpi with 
DENV-4‡††  
41.3 (138) 48.8 (41) 0.7256 
ᶿMean ± SEM reported. 
†Average number of eggs laid per female (Number of females scored; total number of eggs counted). 
ǁPercentage of laid eggs that produced larvae (Number of females scored; total number of larvae counted). 
οPercentage of single male outcrosses that gave rise to viable progeny. 
lAverage number of eggs laid per single male outcross (Number of male outcrosses scored; total number of eggs 
counted). 
ⅢPercentage of laid eggs that produced larvae per single male outcross (Number of male outcrosses scored; total 
number of larvae counted). 
§Unpaired t test with Welch’s correction was used. 
¶Unpaired t test was used to evaluate the statistical significance between the proportions of fertile males. 
††Mantel-Cox test was used. 
‡Percentage of infected mosquitoes surviving at 14 dpi.  
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Supplementary Figures and Tables 
 
Supplementary Figure 1. Expression correlation analyses of gene expression levels (indicated by 
TPM [transcripts per million] values) in dissected midgut tissues from WT or transgenic (TADV-
A, -B, or -C) mosquitoes without a blood meal (A) and 24 hours after a blood meal (B). The y-
axis corresponds to TPM values in WT samples, and the x-axis corresponds to TPM values in 
respective transgenic samples. Blue-colored points represent endogenous genes, and red-colored 
points represent the 1C19 scFv. Comparisons between WT and TADV samples suggest that 1C19 
scFv expression is transgene-dependent and does not appear to significantly affect global 
expression levels of endogenous RNAs. Pearson correlation coefficients (r) between gene 
expression levels in WT versus transgenic samples are reported in bold in their respective graphs.  
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Supplementary Figure 2. Western blot analyses to probe for the presence of the 1C19 scFv 
antibody protein in WT and transgenic midgut samples. Western blots were carried out utilizing a 
custom antibody specific for the 1C19 scFv protein, as well as an antibody to recognize the 3xHA 
tag, on dissected midgut tissues from non-blood-fed or 16-hour post-blood-meal WT or TADV-
A, TADV-B, or TADV-C mosquitoes. An anti-GAPDH antibody was used as a control. The 
presence of a 26.3-kDa band confirms the expression of the 1C19 scFv protein in transgenic, but 
not in WT, mosquito midgut samples. The presence of a 30 kDa band indicates the presence of the 
3xHA tag in TADV-B and TADV-C but not in WT or TADV-A mosquitoes.  
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Supplementary Figure 3.  Effect of the anti-DENV scFv on DENV GE in three independent 
transgenic mosquito lines. DENV GE in WT and transgenic mosquito lines (TADV-A, TADV-B, 
or TADV-C) following a blood meal infected with DENV-2 (ET300 strain) are shown. DENV GE 
from mosquito midguts (at 4 dpi) of WT or transgenic mosquitoes were determined using real-
time qPCR and calculated using previously published methods. Circles represent WT mosquitoes; 
black diamonds represent anti-DENV homozygous transgenic mosquitoes; red colored diamonds 
represent anti-DENV heterozygous transgenic mosquitoes. Horizontal bars represent the mean 
viral titer. The Mantel-Cox test was used for statistical analysis. **p < 0.001. 
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Supplementary Figure 4. Survivorship curves for uninfected WT and TADV-A mosquitoes and 
for DENV-infected WT, wMel, and TADV-A mosquitoes. The x-axis indicates the number of days 
elapsed after the start of the experiment, and the y-axis indicates the percent of mosquitoes 
surviving on each elapsed day. (A) For the uninfected panel, where the survivorship curves for 
WT and TADV-A male and female mosquitoes are shown separately, each line represents the 
accumulated results of 120–180 adult mosquitoes combined from 3 biological replicates. 
Significant differences in survivorship were observed between WT and TADV-A females, with 
WT females surviving, on average, 4.5 days longer (p ≤ 0.01). (B) For the infected panels, WT, 
wMel, and TADV-A females were given a blood meal infected with DENV-1, DENV-2, DENV-
3, or DENV-4 (as indicated on respective plot titles). The survivorship of infected mosquitoes was 
determined over the course of 14 days (the time it takes for the virus to disseminate past the midgut 
and eventually become transmissible). No significant differences in survivorship were found 
between WT and TADV-A mosquitoes when infected with DENV-3 and DENV-4, but significant 
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differences were observed upon infection with DENV-1, with more WT mosquitoes (80%) 
surviving at 14 dpi than TADV-A mosquitoes (~40%; p ≤ 0.01). When infected with DENV-2, 
more wMel mosquitoes (>90%) survived at 14 dpi compared to WT and TADV-A mosquitoes 
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(both ~70%; p < 0.0001). The Mantel-Cox test was used to determine statistical significance. 
*p ≤ 0.01, ***p < 0.0001.  
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Supplementary Table 1. Effect of the anti-DENV scFv on DENV-2 GE in three independent 
mosquito lines. DENV-2 GE are shown below for WT, TADV-A, TADV-B, and TADV-C 
mosquito lines following a blood meal infected with the DENV-2 ET300 strain. Midgut samples 
were collected 4 dpi, and GE were determined using real-time RT-qPCR and calculated using 
previously published methods.  
Mosquito strain GE of virus 
RNA/mosquito midgut at 
4 dpi 
Virus-positive mosquitoes/        
Total mosquitoes (% infection 
rate) 
WT 4.5 x 104 24/26 (92.3%) 
TADV-A 6.1 x 101 17/37 (45.9%) 
TADV-B 1.5 x 102 25/40 (62.5%) 
TADV-C 2.0 x 102 25/35 (71.4%) 
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Supplementary Table 2: Primers utilized to generate anti-DENV scFv used in this study. 
 
Primer  Primer Sequence, 5’ to 3’ Source 
tdTomato marker 
 
984.1A 
 
984.1B 
 
GACGGTACGATCCACCGGTCGCCACCATGGTGAGCAAGGGCGAGG
AGGTCATCAAAGAGT 
TGGTATGGCTGATTATGATCTAGAGTCGCGGCCGCCTACTTGTACAG
CTCGTCCATGCCG 
Gene- 
synthesized 
vector 
Carboxypeptidase 
promoter 
 
984.2A 
  
  
984.2B 
  
ATGGTTAATTCGAGCTCGCCCGGGGTCCTAGGGAATTCGTCAATAA
AAAAATACGTTCAA 
CTCCTCGCCCTTGCTCACCATGTTTAAACTTTCCCAACTAACCGATA
CACACTAACCTG 
Genomic Ae. 
aegypti DNA 
GFP marker 
984.3A 
984.3B 
 
AGTGTGTATCGGTTAGTTGGGAAAGTTTAAACATGGTGAGCAAGGG
CGAGGAGCTGTTCAC 
TGATTTGTTATTTTAAAAACGATTCATTCTAGTTAATTAATTACTTGT
ACAGCTCGTCCATGCC 
pMos[3xP3-
eGFP] 
p10 3’ UTR 
 
984.4A 
 
984.4B 
 
GGACGAGCTGTACAAGTAATTAATTAACTAGAATGAATCGTTTTTA
AAATAACAAAT 
TCCCCGGGCGAGCTCGAATTGGCGCGCCCGGCCGTTAACTCGAATC
GCTATCCAAGC 
pJFRC81-
10XUAS-
IVS-Syn21-
GFP-p10 
G(4)-S linker 
 
984B.C1 
 
984B.C2 
 
TTCGGTCAGGGAACCAAAGTGGATATTAAGGGCGGTTCCGGTGGCA
GCGGCGGCTCCGGTGGCAGCTACCCCTACGACGTGCCCG 
 
TGTTATTTTAAAAACGATTCATTCTAGTTAATTAATCAGGCGTAATC
TGGCACGTCGTAC 
ninaE[SBP-
His] vector 
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Supplementary Table 3. Diagnostic primers used for inverse PCR (iPCR) assays, zygosity 
confirmation, pan-DENV serotype detection, and wMel infection confirmation. 
piggyBac Primers 
Reaction Primer Name Primer Sequence, 5’ to 3’ 
5’ (1st Round PCR) 991.5F1 
GACGCATGATTATCTTTTACGTGAC 
991.5R1 
TGACACTTACCGCATTGACA 
5’(2nd Round PCR) 991.5F2 
GCGATGACGAGCTTGTTGGTG 
991.5R2 
TCCAAGCGGCGACTGAGATG 
3’ (1st Round PCR) 
991.3F1 
CAACATGACTGTTTTTAAAGTACAAA 
991.3R1 
GTCAGAAACAACTTTGGCACATATC 
3’ (2nd Round PCR) 
991.3F2 
CCTCGATATACAGACCGATAAAAC 
991.3R2 
TGCATTTGCCTTTCGCCTTAT 
Zygosity Primers 
Reaction Line Primer 
Name 
Primer Sequence, 5’ to 3’ 
Forward primer TADV-
A 
1018.S19 CCAAGTCGTCAACTTGTGACTG 
TADV-B 1018.S73 TAAAAACATAAACAACGACC 
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TADV-C 1018.S80 GCTCTCACCGTTGAAAATTTAT 
Reverse primer 
TADV-
A 
1018.S21 GGACCCAATTGTTACTACACCTATTTC 
TADV-B 1018.S74 AAAATAAATCATTCTGAGTTTGT 
  
TADV-C 1018.S82 CAGGGTCCTAAAATGTTCAATG 
DENV RT-qPCR Primers 
Primer name Primer Sequence, 5’ to 3’ 
DENV-F 
 
ACGTGCACACATGGACAGA 
DENV-R 
 
ACTGAGCGGATTCCACAAA 
wMel Primers 
Primer name Primer Sequence, 5’ to 3’ 
wMel-F 
CAAATTGCTCTTGTCCTGTGG 
wMel-R 
GGGTGTTAAGCAGAGTTACGG 
 
 
Supplementary Table 4 .Quantification of total RNA expression in WT, TADV-A, TADV-B, 
and TADV-C mosquito midguts prior to blood meal (NBF) and 24-hours post-blood feeding 
(PBM). Both raw read counts and normalized TPM values are included. 
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https://docs.google.com/spreadsheets/d/1Xvuw5xwCwE8_pU_-
coBptAY1hK9DX0GRzAUijRooZvk/edit?usp=sharing 
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